IL309395A - Sequential innate and adaptive immune modulation for cancer treatment - Google Patents
Sequential innate and adaptive immune modulation for cancer treatmentInfo
- Publication number
- IL309395A IL309395A IL309395A IL30939523A IL309395A IL 309395 A IL309395 A IL 309395A IL 309395 A IL309395 A IL 309395A IL 30939523 A IL30939523 A IL 30939523A IL 309395 A IL309395 A IL 309395A
- Authority
- IL
- Israel
- Prior art keywords
- innate
- sequential
- cancer treatment
- adaptive immune
- immune modulation
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000003044 adaptive effect Effects 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000008102 immune modulation Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Physiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21179848.3A EP4104830A1 (en) | 2021-06-16 | 2021-06-16 | Sequential innate and adaptive immune modulation for cancer treatment |
PCT/EP2022/066533 WO2022263618A1 (en) | 2021-06-16 | 2022-06-16 | Sequential innate and adaptive immune modulation for cancer treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
IL309395A true IL309395A (en) | 2024-02-01 |
Family
ID=76942706
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL309395A IL309395A (en) | 2021-06-16 | 2022-06-16 | Sequential innate and adaptive immune modulation for cancer treatment |
Country Status (7)
Country | Link |
---|---|
EP (2) | EP4104830A1 (en) |
JP (1) | JP2024521514A (en) |
CN (1) | CN117794549A (en) |
AU (1) | AU2022292917A1 (en) |
CA (1) | CA3222919A1 (en) |
IL (1) | IL309395A (en) |
WO (1) | WO2022263618A1 (en) |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4843820A (en) | 1988-04-29 | 1989-07-04 | Allied-Signal Inc. | Brake system in-line fast fill valve |
US20030026782A1 (en) | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
DE19935756A1 (en) | 1999-07-27 | 2001-02-08 | Mologen Forschungs Entwicklung | Covalently closed nucleic acid molecule for immune stimulation |
US20060241076A1 (en) | 2005-04-26 | 2006-10-26 | Coley Pharmaceutical Gmbh | Modified oligoribonucleotide analogs with enhanced immunostimulatory activity |
BRPI0618473A2 (en) * | 2005-11-11 | 2011-08-30 | Pfizer | combinations and methods of using an immunomodulatory oligodeoxynucleotide |
US7662949B2 (en) | 2005-11-25 | 2010-02-16 | Coley Pharmaceutical Gmbh | Immunostimulatory oligoribonucleotides |
KR20090058584A (en) | 2006-10-26 | 2009-06-09 | 콜리 파마슈티칼 게엠베하 | Oligoribonucleotides and uses thereof |
ES2750608T3 (en) | 2013-07-25 | 2020-03-26 | Exicure Inc | Nucleic acid-based spherical constructs as immunostimulatory agents for prophylactic and therapeutic use |
EP3392345A1 (en) * | 2017-04-22 | 2018-10-24 | Mologen AG | Biomarker for small cell lung cancer therapy |
EP3691749A1 (en) * | 2017-08-31 | 2020-08-12 | Mologen AG | Tlr-9 agonists for modulation of tumor microenvironment |
-
2021
- 2021-06-16 EP EP21179848.3A patent/EP4104830A1/en not_active Withdrawn
-
2022
- 2022-06-16 WO PCT/EP2022/066533 patent/WO2022263618A1/en active Application Filing
- 2022-06-16 EP EP22734294.6A patent/EP4355337A1/en active Pending
- 2022-06-16 AU AU2022292917A patent/AU2022292917A1/en active Pending
- 2022-06-16 JP JP2023577935A patent/JP2024521514A/en active Pending
- 2022-06-16 CA CA3222919A patent/CA3222919A1/en active Pending
- 2022-06-16 CN CN202280054322.7A patent/CN117794549A/en active Pending
- 2022-06-16 IL IL309395A patent/IL309395A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN117794549A (en) | 2024-03-29 |
JP2024521514A (en) | 2024-05-31 |
EP4355337A1 (en) | 2024-04-24 |
CA3222919A1 (en) | 2022-12-22 |
EP4104830A1 (en) | 2022-12-21 |
AU2022292917A1 (en) | 2024-01-04 |
WO2022263618A1 (en) | 2022-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL261008B1 (en) | Combination immune therapy and cytokine control therapy for cancer treatment | |
IL297418B1 (en) | Combination immune therapy and cytokine control therapy for cancer treatment | |
IL272740A (en) | Combination immune therapy and cytokine control therapy for cancer treatment | |
EP3876965A4 (en) | Combination therapies of microorganisms and immune modulators for use in treating cancer | |
IL275940A (en) | Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer | |
IL281441A (en) | Anti-cxcl13 antibodies for treating autoimmune diseases and cancer | |
FI3773689T3 (en) | Antigenic peptides for prevention and treatment of cancer | |
IL263394A (en) | Methods of activating dysfunctional immune cells and treatment of cancer | |
EP3752528A4 (en) | Cancer treatment using combination of neutrophil modulator with modulator of immune checkpoint | |
SG11202005296SA (en) | Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer | |
IL309395A (en) | Sequential innate and adaptive immune modulation for cancer treatment | |
GB201810635D0 (en) | Peptides and cancer treatment | |
IL286326A (en) | Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer | |
EP4084822A4 (en) | Individualized vaccines for cancer treatment and prevention | |
IL288591A (en) | Methods and uses for treating cancer | |
IL287923A (en) | Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating luts | |
SG11202103148QA (en) | Methods of treating residual breast cancer with trastuzumab emtansine | |
GB201815694D0 (en) | Prevention and treatment of cancer | |
GB201809946D0 (en) | Prevention and treatment of cancer | |
SG11202108140SA (en) | Anti-bag2 antibody and methods of treating cancer | |
GB202303784D0 (en) | Cancer treatment | |
GB202217305D0 (en) | Cancer treatment | |
GB202211123D0 (en) | Cancer treatment | |
GB202210038D0 (en) | Cancer treatment | |
GB202206948D0 (en) | Cancer treatment |